FDA Defines ‘Controlled Correspondence’ for Generics to Receive Timely Responses

Drug Industry Daily
A A
The FDA is explaining how generics firms can receive timely responses to their requests for information in a guidance that defines a new communications process known as “controlled correspondence.”

To View This Article:

Login

Subscribe To Drug Industry Daily